Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus.
Margison, Geoffrey P
Hermann, F G
Von Laer, D
AffiliationDepartment of Hematology, Hemostaseology and Oncology, Hannover Medical School, Hannover, Germany.
MetadataShow full item record
AbstractThe failure of pharmacological approaches to cure infection with the human immunodeficiency virus (HIV) has renewed the interest in gene-based therapies. Among the various strategies that are currently explored, the blockade of HIV entry into susceptible T cells and macrophages promises to be the most powerful intervention. For long-term protection of both of these lineages, genetic modification of hematopoietic stem cells (HSCs) would be required. Here, we tested whether HSCs and their progeny can be modified to express therapeutic levels of M87o, a gammaretroviral vector encoding an artificial transmembrane molecule that blocks fusion-mediated uptake of HIV. In serial murine bone marrow transplantations, efficient and multilineage expression of M87o was observed for more than 1 year (range 37-75% of mononuclear cells), without signs of toxicity related to the transmembrane molecule. To allow enrichment of M87o-modified HSCs after transplant, we constructed vectors coexpressing the P140K mutant of O(6)-methylguanine-DNA-methyltransferase (MGMT-P140K). This clinically relevant selection marker mediates a survival advantage in HSCs if exposed to combinations of methylguanine-methyltransferase (MGMT) inhibitors and alkylating agents. A bicistronic vector mediated sufficient expression of both M87o and MGMT to confer a selective survival advantage in the presence of HIV and alkylating agents, respectively. These data encourage further investigations in large animal models and clinical trials.
CitationTowards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. 2006, 13 (13):1037-47 Gene Ther.
- Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
- Authors: Jansen M, Sorg UR, Ragg S, Flasshove M, Seeber S, Williams DA, Moritz T
- Issue date: 2002 Sep
- Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
- Authors: Kramer BA, Lemckert FA, Alexander IE, Gunning PW, McCowage GB
- Issue date: 2006 Sep
- Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
- Authors: Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA, Baum C
- Issue date: 2006 Feb
- Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro.
- Authors: Su L, Lee R, Bonyhadi M, Matsuzaki H, Forestell S, Escaich S, Böhnlein E, Kaneshima H
- Issue date: 1997 Apr 1
- Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
- Authors: Sakurai F, Kawabata K, Yamaguchi T, Hayakawa T, Mizuguchi H
- Issue date: 2005 Oct